Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25652161 | 0.85 | UHRF1 (0.42) | NOS3NOS1NOS2DHFRALDH1A1 | |
| SCHEMBL21558452 | 0.76 | ALDH1A1 (0.39) | DHFRALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7117731 | 0.73 | NOS3 (0.48) | NOS3NOS1NOS2DHFRSLC6A2 | |
| SCHEMBL5659078 | 0.72 | MEN1 (0.53) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL25652151 | 0.71 | NOS3 (0.37) | NOS3NOS1NOS2DHFRALDH1A1 | |
| SCHEMBL25652147 | 0.71 | ALDH1A1 (0.37) | NOS3NOS2DHFRALDH1A1MEN1 | |
| SCHEMBL14917587 | 0.70 | NOS3 (0.47) | NOS3NOS1NOS2DHFRSLC6A2 | |
| SCHEMBL25652154 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2DHFRSMN1; SMN2 | |
| SCHEMBL5655615 | 0.69 | SMN1; SMN2 (0.50) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8934135 | 0.68 | NOS3 (0.53) | NOS3NOS1NOS2DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | NOS3 1523/4885NOS1 1826/4885NOS2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.